Q1 2025 Day One Biopharmaceuticals Inc Earnings Call Transcript
Key Points
- OJEMDA achieved significant growth with over 900 quarterly scripts, representing a 16% increase over the previous quarter.
- Net product revenue for OJEMDA reached $30.5 million in Q1 2025, driven by strong prescriber adoption and high payer approval rates.
- The FIREFLY-2 confirmatory trial is progressing well, with full enrollment expected in the first half of 2026.
- Day One Biopharmaceuticals Inc (DAWN) maintains a strong financial position with a cash balance of $473 million and no debt.
- The company is actively evaluating business development opportunities to expand its clinical stage portfolio and drive long-term growth.
- Operating expenses, excluding cost of sales, were high at $68.9 million in Q1 2025, including $12.9 million in noncash stock-based compensation.
- Seasonality affected Q1 performance, with a slower start in January due to holidays impacting scans and new treatment initiations.
- Gross to net adjustments were closer to the higher end of the 12% to 15% range, partly due to a price increase and additional co-pay assistance.
- The market adoption of OJEMDA is gradual, akin to a rare disease launch, due to the infrequency of treatment decisions and longer treatment durations.
- There is entrenched use of existing therapies, such as chemotherapy and MEK inhibitors, which presents a hurdle to establishing OJEMDA as the second-line standard of care.
Hello, ladies and gentlemen, and welcome to the Day One Biopharmaceuticals first quarter 2025 financial And operating results conference call. (Operator Instructions) Please be advised that this conference call is being recorded. I would now like to turn the call over to Joey Perrone, Senior Vice President of Finance and Investor Relations. Please begin.
Thank you. Hello, everyone, and good afternoon. Welcome to Day One's first quarter financial and operating results conference call. Earlier today, we issued a press release, which outlines the topics we plan to discuss. You can access the press release and the slides to accompany this conference call on the Investors and Media section of our website at www.dayonebio.com.
An audio webcast with the corresponding slides is also available on the website. Before we get started, I'd like to remind everyone that some of the statements that we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
